Articles on this Open Access Online Scientific Journal

2/2012 — 1/2013

SNAP: Predict Effect of Non-synonymous Polymorphisms: How well Genome Interpretation Tools could Translate to the Clinic

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/02/03/snap-predict-effect-of-non-synonymous-polymorphisms-how-well-genome-interpretation-tools-could-translate-to-the-clinic/

Drugging the Epigenome

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/02/01/drugging-the-epigenome/

Big Data in Genomic Medicine

Larry H. BernStein, MD

http://pharmaceuticalintelligence.com/2012/12/17/big-data-in-genomic-medicine/

Computational Genomics Center: New Unification of Computational Technologies at Stanford

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/12/03/computational-genomics-center-new-unification-of-computational-technologies-at-stanford/

Personalized medicine gearing up to tackle cancer

Ritu Saxena, PhD

http://pharmaceuticalintelligence.com/2013/01/07/personalized-medicine-gearing-up-to-tackle-cancer/

Personalized Medicine: Cancer Cell Biology and Minimally Invasive Surgery (MIS)

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/12/01/personalized-medicine-cancer-cell-biology-and-minimally-invasive-surgery-mis/

Nanotechnology, personalized medicine and DNA sequencing

Tilda Barlyia, PhD.http://pharmaceuticalintelligence.com/2013/01/09/nanotechnology-personalized-medicine-and-dna-sequencing/

Paradigm Shift in Human Genomics – Predictive Biomarkers and Personalized Medicine – Part 1

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/paradigm-shift-in-human-genomics-predictive-biomarkers-and-personalized-medicine-part-1/

LEADERS in Genome Sequencing of Genetic Mutations for Therapeutic Drug Selection in Cancer Personalized Treatment: Part 2

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/leaders-in-genome-sequencing-of-genetic-mutations-for-therapeutic-drug-selection-in-cancer-personalized-treatment-part-2/

Personalized Medicine: An Institute Profile – Coriell Institute for Medical Research: Part 3

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/personalized-medicine-an-institute-profile-coriell-institute-for-medical-research-part-3/

The Consumer Market for Personal DNA Sequencing: Part 4

AvivaLev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/consumer-market-for-personal-dna-sequencing-part-4/

Harnessing Personalized Medicine for Cancer Management, Prospects of Prevention and Cure: Opinions of Cancer Scientific Leaders @http://pharmaceuticalintelligence.com

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/7000/

GSK for Personalized Medicine using Cancer Drugs needs Alacris systems biology model to determine the in silico effect of the inhibitor in its “virtual clinical trial”

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/11/14/gsk-for-personalized-medicine-using-cancer-drugs-needs-alacris-systems-biology-model-to-determine-the-in-silico-effect-of-the-inhibitor-in-its-virtual-clinical-trial/

Personalized medicine-based cure for cancer might not be far away

Ritu Saxena, PhD

http://pharmaceuticalintelligence.com/2012/11/20/personalized-medicine-based-cure-for-cancer-might-not-be-far-away/

Human Variome Project: encyclopedic catalog of sequence variants indexed to the human genome sequence

Aviva Lev-Ari, PhD, http://pharmaceuticalintelligence.com/2012/11/24/human-variome-project-encyclopedic-catalog-of-sequence-variants-indexed-to-the-human-genome-sequence/

Inspiration From Dr. Maureen Cronin’s Achievements in Applying Genomic Sequencing to Cancer Diagnostics

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/10/inspiration-from-dr-maureen-cronins-achievements-in-applying-genomic-sequencing-to-cancer-diagnostics/

The “Cancer establishments” examined by James Watson, co-discoverer of DNA w/Crick, 4/1953

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/09/the-cancer-establishments-examined-by-james-watson-co-discover-of-dna-wcrick-41953/

Nanotech Therapy for Breast Cancer

Tilda Barlyia, PhD, RN

http://pharmaceuticalintelligence.com/2012/12/09/naotech-therapy-for-breast-cancer/

Hypothesis – following on James Watson

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2013/01/27/novel-cancer-h…ts-are-harmful/

Otto Warburg, A Giant of Modern Cellular Biology

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2012/11/02/otto-warburg-a-giant-of-modern-cellular-biology/

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2012/10/17/is-the-warburg-effect-the-cause-or-the-effect-of-cancer-a-21st-century-view/

Directions for Genomics in Personalized Medicine

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2013/01/27/directions-for-genomics-in-personalized-medicine/

How mobile elements in “Junk” DNA promote cancer. Part 1: Transposon-mediated tumorigenesis,

Steven J Williams, PhD

http://pharmaceuticalintelligence.com/2012/10/31/how-mobile-elements-in-junk-dna-prote-cacner-part1-transposon-mediated-tumorigenesis/

Advances in Separations Technology for the “OMICs” and Clarification of Therapeutic Targets

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2012/10/22/advances-in-separations-technology-for-the-omics-and-clarification-of-therapeutic-targets/

mRNA Interference with Cancer Expression

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2012/10/26/mrna-interference-with-cancer-expression/

Expanding the Genetic Alphabet and linking the Genome to the Metabolome

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2012/09/24/expanding-the-genetic-alphabet-and-linking-the-genome-to-the-metabolome/

Ubiquinin-Proteosome Pathway, Autophagy, the Mitochondrion, Proteolysis and Cell Apoptosis

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2012/10/30/ubiquinin-proteosome-pathway-autophagy-the-mitochondrion-proteolysis-and-cell-apoptosis/

Identification of Biomarkers that are Related to the Actin Cytoskeleton

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2012/12/10/identification-of-biomarkers-that-are-related-to-the-actin-cytoskeleton/

Genomic Analysis: FLUIDIGM Technology in the Life Science and Agricultural Biotechnology

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/08/22/genomic-analysis-fluidigm-technology-in-the-life-science-and-agricultural-biotechnology/

Genome-Wide Detection of Single-Nucleotide and Copy-Number Variation of a Single Human Cell

Stephen J. Williams, Ph.D.

http://pharmaceuticalintelligence.com/2013/02/03/genome-wide-detection-of-single-nucleotide-and-copy-number-variation-of-a-single-human-cell/

How mobile elements in “Junk” DNA promote cancer. Part 1: Transposon-mediated tumorigenesis.

Stephen J. Williams, Ph.D.

http://pharmaceuticalintelligence.com/2012/10/31/how-mobile-elements-in-junk-dna-prote-cacner-part1-transposon-mediated-tumorigenesis/

Cancer Genomics – Leading the Way by Cancer Genomics Program at UC Santa Cruz

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/10/29/cancer-genomics-leading-the-way-by-cancer-genomics-program-at-uc-santa-cruz/

Genome and Genetics: Resources @Stanford, @MIT, @NIH’s NCBCS

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/09/18/genome-and-genetics-resources/

Head and Neck Cancer Studies Suggest Alternative Markers More Prognostically Useful than HPV DNA Testing

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/09/18/head-and-neck-cancer-studies-suggest-alternative-markers-more-prognostically-useful-than-hpv-dna-testing/

Genome-Wide Detection of Single-Nucleotide and Copy-Number Variation of a Single Human Cell

Stephen J. Williams, Ph.D

http://pharmaceuticalintelligence.com/2013/02/03/genome-wide-detection-of-single-nucleotide-and-copy-number-variation-of-a-single-human-cell/

Congestive Heart Failure & Personalized Medicine: Two-gene Test predicts response to Beta Blocker Bucindolol

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/10/17/chronic-heart-failure-personalized-medicine-two-gene-test-predicts-response-to-beta-blocker-bucindolol/

Personalized Medicine as Key Area for Future Pharmaceutical Growth

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/09/18/personalized-medicine-as-key-area-for-future-pharmaceutical-growth/

Gene Therapy Into Healthy Heart Muscle: Reprogramming Scar Tissue In Damaged Hearts

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/09/gene-therapy-into-healthy-heart-muscle-reprogramming-scar-tissue-in-damaged-hearts/

Telling NO to Cardiac Risk

DDAH Says NO to ADMA(1); The DDAH/ADMA/NOS Pathway(2)

Stephen J. Williams, Ph.D

http://pharmaceuticalintelligence.com/2012/12/10/telling-no-to-cardiac-risk/

Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/11/13/peroxisome-proliferator-activated-receptor-ppar-gamma-receptors-activation-pparγ-transrepression-for-angiogenesis-in-cardiovascular-disease-and-pparγ-transactivation-for-treatment-of-dia/

Mitochondrial Damage and Repair under Oxidative Stress

Larry H. Bernstein, MD

http://pharmaceuticalintelligence.com/2012/10/28/mitochondrial-damage-and-repair-under-oxidative-stress/

Reveals from ENCODE project will invite high synergistic collaborations to discover specific targets

Anamika Sarkar, Ph.D

http://pharmaceuticalintelligence.com/2012/09/30/reveals-from-encode-project-will-lead-to-confusion-or-specific-target/

ENCODE: the key to unlocking the secrets of complex genetic diseases

Ritu Saxena, PhD

http://pharmaceuticalintelligence.com/2012/09/26/encode-the-key-to-unlocking-the-secrets-of-complex-genetic-diseases/

Impact of evolutionary selection on functional regions: The imprint of evolutionary selection on ENCODE regulatory elements is manifested between species and within human populations

Dr. Sudipta Saha, Ph.D.

http://pharmaceuticalintelligence.com/2012/09/20/impact-of-evolutionary-selection-on-functional-regions-the-imprint-of-evolutionary-selection-on-encode-regulatory-elements-is-manifested-between-species-and-within-human-populations/

ENCODE Findings as Consortium

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/09/10/encode-findings-as-consortium/

Nation’s Biobanks: Academic institutions, Research institutes and Hospitals – vary by Collections Size, Types of Specimens and Applications: Regulations are Needed

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/26/nations-biobanks-academic-institutions-research-institutes-and-hospitals-vary-by-collections-size-types-of-specimens-and-applications-regulations-are-needed/

Genomic Endocrinology and its Future

Dr. Sudipta Saha, Ph.D.

http://pharmaceuticalintelligence.com/2012/12/27/genomic-endocrinology-and-its-future-2/

Imatinib (Gleevec) May Help Treat Aggressive Lymphoma: Chronic Lymphocytic Leukemia (CLL)

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/11/04/imatinib-gleevec-may-help-treat-aggressive-lymphoma-chronic-lymphocytic-leukemia-cll/

Metabolite Identification Combining Genetic and Metabolic Information: Genetic association links unknown metabolites to functionally related genes

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/10/22/metabolite-identification-combining-genetic-and-metabolic-information-genetic-association-links-unknown-metabolites-to-functionally-related-genes/

DNA – The Next-Generation Storage Media for Digital Information

Sudipta Saha, PhD

http://pharmaceuticalintelligence.com/2012/08/27/dna-the-next-generation-storage-media-for-digital-information/

Angiogenic Disease Research Utilizing microRNA Technology: UCSD and Regulus Therapeutics

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/08/15/angiogenic-disease-research-utilizing-microrna-technology-ucsd-and-regulus-therapeuti/

A microRNA Prognostic Marker Identified in Acute Leukemia

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/05/17/a-microrna-prognostic-marker-identified-in-acute-leukemia/

Exome sequencing of serous endometrial tumors shows recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

Sudipta Saha, Ph.D

http://pharmaceuticalintelligence.com/2012/12/18/exome-sequencing-of-serous-endometrial-tumors-shows-recurrent-somatic-mutations-in-chromatin-remodeling-and-ubiquitin-ligase-complex-genes/

Personal Recombination Map from Individual’s Sperm Cell and its Importance

Sudipta Saha, Ph.D

http://pharmaceuticalintelligence.com/2012/07/23/personal-recombination-map-from-individuals-sperm-cell-and-its-importance/

Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4

Sudipta Saha, Ph.D
http://pharmaceuticalintelligence.com/2012/09/10/targeted-tumor-penetrating-sirna-nanocomplexes-for-credentialing-the-ovarian-cancer-oncogene-id4/

Impact of evolutionary selection on functional regions: The imprint of evolutionary selection on ENCODE regulatory elements is manifested between species and within human populations

Sudipta Saha, Ph.D

 

http://pharmaceuticalintelligence.com/2012/09/20/impact-of-evolutionary-selection-on-functional-regions-the-imprint-of-evolutionary-selection-on-encode-regulatory-elements-is-manifested-between-species-and-within-human-populations/

Gene Trap Mutagenesis in Reproductive Research

Sudipta Saha, Ph.D

http://pharmaceuticalintelligence.com/2012/10/18/gene-trap-mutagenesis-in-reproductive-research/#comment-3310

Pregnancy with a Leptin-Receptor Mutation

Sudipta Saha, Ph.D

http://pharmaceuticalintelligence.com/2012/10/31/pregnancy-with-a-leptin-receptor-mutation/

Genetics and male endocrinology

Sudipta Saha, Ph.D

http://pharmaceuticalintelligence.com/2012/11/12/genetics-and-male-endocrinology/

Recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes in serous endometrialtumors

Sudipta Saha, Ph.D

http://pharmaceuticalintelligence.com/2012/11/19/recurrent-somatic-mutations-in-chromatin-remodeling-and-ubiquitin-ligase-complex-genes-in-serous-endometrial-tumors/

 

BRCA1 a tumour suppressor in breast and ovarian cancer – functions in transcription, ubiquitination and DNA repair

Sudipta Saha, Ph.D

 

http://pharmaceuticalintelligence.com/2012/12/04/brca1-a-tumour-suppressor-in-breast-and-ovarian-cancer-functions-in-transcription-ubiquitination-and-dna-repair/

 

Genomic Endocrinology and its Future

Sudipta Saha, Ph.D

http://pharmaceuticalintelligence.com/2012/12/27/genomic-endocrinology-and-its-future-2/

Commentary on Dr. Baker’s post “Junk DNA codes for valuable miRNAs: non-coding DNA controls Diabetes”

Ritu Saxena, PhD

http://pharmaceuticalintelligence.com/2012/10/03/commentary-on-dr-bakers-post-junk-dna-codes-for-valuable-mirnas-non-coding-dna-controls-diabetes/

Obstructive coronary artery disease diagnosed by RNA levels of 23 genes – CardioDx heart disease test wins Medicare coverage

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/08/14/obstructive-coronary-artery-disease-diagnosed-by-rna-levels-of-23-genes-cardiodx-heart-disease-test-wins-medicare-coverage/

Potential Drug Target: Glucolysis Regulation – Oxidative stress-responsive microRNA-320

http://pharmaceuticalintelligence.com/2012/07/25/potential-drug-target-glucolysis-regulation-oxidative-stress-responsive-microrna-320

Winning Over Cancer Progression: New Oncology Drugs to Suppress Passengers Mutations vs. Driver Mutations

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/02/05/winning-over-cancer-progression-new-oncology-drugs-to-suppress-driver-mutations-vs-passengers-mutations/

Genomics and NGS

“Genome in a Bottle”: NIST’s new metrics for Clinical Human Genome Sequencing “Genome in a Bottle”: NIST’s new metrics for Clinical Human Genome Sequencing

http://pharmaceuticalintelligence.com/2012/09/06/genome-in-a-bottle-nists-new-metrics-for-clinical-human-genome-sequencing/

DNA – The Next-Generation Storage Media for Digital Information

http://pharmaceuticalintelligence.com/2012/08/27/dna-the-next-generation-storage-media-for-digital-information/

How Genome Sequencing is Revolutionizing Clinical Diagnostics

http://pharmaceuticalintelligence.com/2012/08/20/how-genome-sequencing-is-revolutionizing-clinical-diagnostics/

NGS Market: Trends and Development for Genotype-Phenotype Associations Research

http://pharmaceuticalintelligence.com/2013/02/19/ngs-market-trends-and-development-for-genotype-phenotype-associations/

What is the Future for Genomics in Clinical Medicine?

http://pharmaceuticalintelligence.com/2013/02/17/what-is-the-future-for-genomics-in-clinical-medicine/

Genomically Guided Treatment after CLIA Approval: to be offered by Weill Cornell Precision Medicine Institute

http://pharmaceuticalintelligence.com/2013/02/06/genomically-guided-treatment-after-clia-approval-to-be-offered-by-weill-cornell-precision-medicine-institute/

Inaugural Genomics in Medicine – The Conference Program, 2/11-12/2013, San Francisco, CA

http://pharmaceuticalintelligence.com/2013/02/04/inaugural-genomics-in-medicine-the-conference-program-211-122013-san-francisco-ca/

GSK for Personalized Medicine using Cancer Drugs needs Alacris systems biology model to determine the in silico effect of the inhibitor in its “virtual clinical trial”

http://pharmaceuticalintelligence.com/2012/11/14/gsk-for-personalized-medicine-using-cancer-drugs-needs-alacris-systems-biology-model-to-determine-the-in-silico-effect-of-the-inhibitor-in-its-virtual-clinical-trial/

arrayMap: Genomic Feature Mining of Cancer Entities of Copy Number Abnormalities (CNAs) Data

http://pharmaceuticalintelligence.com/2012/11/01/arraymap-genomic-feature-mining-of-cancer-entities-of-copy-number-abnormalities-cnas-data/

NGS Cardiovascular Diagnostics: Long-QT Genes Sequenced – A Potential Replacement for Molecular Pathology

http://pharmaceuticalintelligence.com/2012/10/01/ngs-cardiovascular-diagnostics-long-qt-genes-sequenced-a-potential-replacement-for-molecular-pathology/

Speeding Up Genome Analysis: MIT Algorithms for Direct Computation on Compressed Genomic Datasets

http://pharmaceuticalintelligence.com/2012/09/18/speeding-up-genome-analysis-mit-algorithms-for-direct-computation-on-compressed-genomic-datasets/

Clinical Genetics, Personalized Medicine, Molecular Diagnostics, Consumer-targeted DNA – Consumer Genetics Conference (CGC) – October 3-5, 2012, Seaport Hotel, Boston, MA

http://pharmaceuticalintelligence.com/2012/09/06/clinical-genetics-personalized-medicine-molecular-diagnostics-consumer-targeted-dna-consumer-genetics-conference-cgc-october-3-5-2012-seaport-hotel-boston-ma/

“CRACKING THE CODE OF HUMAN LIFE: The Birth of BioInformatics & Computational Genomics” lays the manifold multivariate systems analytical tools that has moved the science forward to a groung that ensures clinical application.

http://pharmaceuticalintelligence.com/2013/02/13/cracking-the-code-of-human-life-the-birth-of-bioinformatics-and-computational-genomics/

REFERENCES on Genomics by Subject Matter

Genome and Mathematics

Akavia, U.D., Litvin, O., Kim, J., Sanchez-Garcia, F., Kotliar, D., Causton,

H.C., Pochanard, P., Mozes, E., Garraway, L.A., and Pe’er,

D. (2010). An integrated approach to uncover drivers of cancer.

Cell 143, 1005–1017.

Alexaki, V.I., Javelaud, D., Van Kempen, L.C. et al. (2010). GLI2-

mediated melanoma invasion and metastasis. J. Natl Cancer Inst.

102, 1148–1159.

Arozarena, I., Sanchez-Laorden, B., Packer, L., Hidalgo-Carcedo, C.,

Hayward, R., Viros, A., Sahai, E., and Marais, R. (2011). Oncogenic

BRAF induces melanoma cell invasion by downregulating

the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19,

45–57.

Buoni, S., Zannolli, R., De Santi, M. et al. (2006). Neurocutaneous

syndrome with mental delay, autism, blockage in intracellular

vescicular trafficking and melanosome defects. Eur. J. Neurol.

13, 842–851.

Chiaverini, C., Beuret, L., Flori, E., Busca, R., Abbe, P., Bille, K., Bahadoran,

P., Ortonne, J.P., Bertolotto, C., and Ballotti, R. (2008).

Microphthalmia-associated transcription factor regulates RAB27A

gene expression and controls melanosome transport. J. Biol.

Chem. 283, 12635–12642.

Chin, L., Tam, A., Pomerantz, J. et al. (1999). Essential role for

oncogenic Ras in tumour maintenance. Nature 400, 468–472.

Chin, L., Garraway, L.A., and Fisher, D.E. (2006). Malignant melanoma:

genetics and therapeutics in the genomic era. Genes Dev.

20, 2149–2182.

Colombo, S., Champeval, D., Rambow, F., and Larue, L. (2011).

Transcriptomic Analysis of Mouse Embryonic Skin Cells Reveals

Previously Unreported Genes Expressed in Melanoblasts. J.

Invest. Dermatol. doi: 10.1038/jid.2011.252.

Dennler, S., Andre, J., Verrecchia, F., and Mauviel, A. (2009). Cloning

of the human GLI2 Promoter: transcriptional activation by

transforming growth factor-beta via SMAD3 ⁄ beta-catenin cooperation.

J. Biol. Chem. 284, 31523–31531.

Fagiani, E., Giardina, G., Luzi, L. et al. (2007). RaLP, a new member

of the Src homology and collagen family, regulates cell migration

and tumor growth of metastatic melanomas. Cancer Res. 67,

3064–3073.

Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative

genomic analyses identify MITF as a lineage survival oncogene

amplified in malignant melanoma. Nature 436, 117–122.

Goodall, J., Carreira, S., Denat, L., Kobi, D., Davidson, I., Nuciforo,

P., Sturm, R.A., Larue, L., and Goding, C.R. (2008). Brn-2

represses microphthalmia-associated transcription factor expression

and marks a distinct subpopulation of microphthalmia-associated

transcription factor-negative melanoma cells. Cancer Res.

68, 7788–7794.

Hawley, S.P., Wills, M.K., Rabalski, A.J., Bendall, A.J., and Jones,

N. (2011). Expression patterns of ShcD and Shc family adaptor

proteins during mouse embryonic development. Dev. Dyn. 240,

221–231.

Hoek, K.S., and Goding, C.R. (2010). Cancer stem cells versus phenotype-

switching in melanoma. Pigment Cell Melanoma Res. 23,

746–759.

Ingram, J.L., Stodgell, C.J., Hyman, S.L., Figlewicz, D.A., Weitkamp,

L.R., and Rodier, P.M. (2000). Discovery of allelic variants

of HOXA1 and HOXB1: genetic susceptibility to autism spectrum

disorders. Teratology 62, 393–405.

Kabbarah, O., Nogueira, C., Feng, B. et al. (2010). Integrative genome

comparison of primary and metastatic melanomas. PLoS

ONE 5, e10770.

Luchin, A., Purdom, G., Murphy, K., Clark, M.Y., Angel, N., Cassady,

A.I., Hume, D.A., and Ostrowski, M.C. (2000). The microphthalmia

transcription factor regulates expression of the tartrateresistant

acid phosphatase gene during terminal differentiation of

osteoclasts. J. Bone Miner. Res. 15, 451–460.

Mcmahon, M. (2011). Parsing out the complexity of RAF inhibitor

resistance. Pigment Cell Melanoma Res. 24, 361–365.

Pinner, S., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais,

R., Bonvin, E., Goding, C., and Sahai, E. (2009). Intravital imaging

reveals transient changes in pigment production and Brn2

expression during metastatic melanoma dissemination. Cancer

Res. 69, 7969–7977.

Santiago-Walker, A., and Herlyn, M. (2010). The ups and downs of

transcription factors in melanoma. J. Natl Cancer Inst. 102,

1103–1104.

Scott, K.L., Nogueira, C., Heffernan, T.P. et al. (2011). Proinvasion

metastasis drivers in early-stage melanoma are oncogenes. Cancer

Cell 20, 92–103.

Strub, T., Giuliano, S., Ye, T. et al. (2011). Essential role of Microphthalmia

transcription factor for DNA replication, mitosis and

genomic stability in melanoma. Oncogene 30, 2319–32.

Commentary

ª